Logotype for WELL Health Technologies Corp

WELL Health Technologies (WELL) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for WELL Health Technologies Corp

Q4 2025 earnings summary

20 Mar, 2026

Executive summary

  • Achieved record annual revenue of CAD 1.4 billion ($1.40B) in FY2025, up 52% year-over-year, with Adjusted EBITDA of CAD 203.7 million ($203.7M), up 336%, and Adjusted Net Income of CAD 126.5 million ($0.50 per share), up 1,479% year-over-year.

  • Delivered 10.5 million care interactions, 4.3 million Canadian patient visits, and expanded to 252 clinics nationwide, adding 44 clinics and 307 providers in 2025 through M&A.

  • WELLTRUST platform launched, enabling AI-powered patient identification for clinical research, with 30,000 patient consents and 56 clinics live.

  • Strategic review of U.S. assets underway, with active divestiture discussions for WISP, Circle Medical, and CRH.

  • WELLSTAR subsidiary delivered strong SaaS growth and is planned for a spin-out to unlock shareholder value.

Financial highlights

  • Normalized 2025 revenue was CAD 1.35 billion ($1.35B), up 34% year-over-year, with Normalized Adjusted EBITDA of CAD 148.6 million ($148.6M), up 17%, and Normalized Adjusted Net Income of CAD 99 million, up 102%.

  • Adjusted EBITDA margin improved to 14.5% from 5.1% in 2024; Adjusted Gross Margin reached 44.2% in 2025.

  • Free cash flow attributable to shareholders was CAD 58.2 million ($58.2M), up 19% year-over-year.

  • WELLSTAR revenue grew 63% to CAD 72.9 million ($72.9M), with 30% Adjusted EBITDA margin.

  • HEALWELL contributed CAD 112.9 million in revenue, with Q4 revenue up 374% year-over-year and positive Adjusted EBITDA.

Outlook and guidance

  • 2026 revenue guidance: CAD 1.55–1.65 billion ($1.55–$1.65B), with Adjusted EBITDA of CAD 175–185 million ($175–$185M), targeting at least 10% annual growth in Adjusted EBITDA and free cash flow.

  • WELL Canada targeting over CAD 800 million ($800M) in revenue and CAD 100 million ($100M) in Adjusted EBITDA within 18 months.

  • Guidance excludes unannounced M&A and is sensitive to timing of acquisitions and divestitures.

  • Continued focus on Canadian M&A and planned WELLSTAR spin-out, subject to market conditions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more